RT Conference Proceedings
T1 SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
A1 Ciruelos, E. M.
A1 Gonzalez-Farre, X.
A1 Perello, A.
A1 Alba, E.
A1 Palacios-Ozores, P.
A1 Salvador-Bofil, J.
A1 Merino, M.
A1 Villagrasa, P.
A1 Celiz, P.
A1 Pascual, T.
A1 Prat, A.
A1 Pernas Simon, S.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-05-01
LK https://hdl.handle.net/10668/27095
UL https://hdl.handle.net/10668/27095
LA en
DS RISalud
RD Apr 7, 2025